MINI LONG - CAMS AB Share Price

Certificat

MINI L CAMURUS

GB00BQRCFS36

Market Closed - Bid/Ask 14:17:23 16/05/2024 BST			After market 16:25:00
374.6 ^SEK	+30.44%		355.2	-5.19%

3 months	+51.54%
6 months	+50.83%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart CAMURUS AB

Latest news about CAMURUS AB

Camurus to present at Jefferies 2024 Healthcare Conference New York	09:01am	AQ
Camurus' Rare Growth Disorder Drug Accepted for Review in EU	05-23	MT
Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly	05-23	AQ
Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot for the Treatment of Acromegaly	05-23	CI

More news

Static data

Product type	Knock-Out with Stop Loss
Buy / Sell	CALL
Underlying	CAMURUS AB
Issuer	Morgan Stanley
	MINI L CAMURUS
ISIN	GB00BQRCFS36
Date issued	13/04/2023
Strike	192.4 kr
Maturity	Unlimited
Parity	1 : 1
Emission price	- kr
Emission volume	N/A
Settlement	cash
Currency	SEK

Technical Indicators

Highest since issue	382.2 kr
Lowest since issue	42.94 kr
Spread	3.04 kr
Spread %	0.85%

Company Profile

Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Companyâs products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.

Sector

More about the company